Literature DB >> 24766321

Improving early cycle economic evaluation of diagnostic technologies.

Lotte M G Steuten1, Scott D Ramsey.   

Abstract

The rapidly increasing range and expense of new diagnostics, compels consideration of a different, more proactive approach to health economic evaluation of diagnostic technologies. Early cycle economic evaluation is a decision analytic approach to evaluate technologies in development so as to increase the return on investment as well as patient and societal impact. This paper describes examples of 'early cycle economic evaluations' as applied to diagnostic technologies and highlights challenges in its real-time application. It shows that especially in the field of diagnostics, with rapid technological developments and a changing regulatory climate, early cycle economic evaluation can have a guiding role to improve the efficiency of the diagnostics innovation process. In the next five years the attention will move beyond the methodological and analytic challenges of early cycle economic evaluation towards the challenge of effectively applying it to improve diagnostic research and development and patient value. Future work in this area should therefore be 'strong on principles and soft on metrics', that is, the metrics that resonate most clearly with the various decision makers in this field.

Entities:  

Keywords:  decision makers; diagnostics; economic evaluation; value of information

Mesh:

Year:  2014        PMID: 24766321     DOI: 10.1586/14737167.2014.914435

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  9 in total

1.  A call for pharmacogenovigilance and rapid falsification in the age of big data: why not first road test your biomarker?

Authors:  Semra Şardaş; Laszlo Endrenyi; Ulvi K Gürsoy; Mara Hutz; Biaoyang Lin; George P Patrinos; Lotte M G Steuten; Wei Wang; Louise Warnich; Vural Özdemir
Journal:  OMICS       Date:  2014-10-29

2.  Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine.

Authors:  Lotte M G Steuten
Journal:  OMICS       Date:  2016-01

3.  Multi-Dimensional Impact of the Public-Private Center for Translational Molecular Medicine (CTMM) in the Netherlands: Understanding New 21(st) Century Institutional Designs to Support Innovation-in-Society.

Authors:  Lotte M Steuten
Journal:  OMICS       Date:  2016-05

4.  Knee Joint Distraction Compared to Total Knee Arthroplasty for Treatment of End Stage Osteoarthritis: Simulating Long-Term Outcomes and Cost-Effectiveness.

Authors:  J A D van der Woude; S C Nair; R J H Custers; J M van Laar; N O Kuchuck; F P J G Lafeber; P M J Welsing
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

5.  Development of a web-based tool for the assessment of health and economic outcomes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA).

Authors:  Christian E H Boehler; Gimon de Graaf; Lotte Steuten; Yaling Yang; Fabienne Abadie
Journal:  BMC Med Inform Decis Mak       Date:  2015-09-04       Impact factor: 2.796

6.  The economic case for precision medicine.

Authors:  Sean P Gavan; Alexander J Thompson; Katherine Payne
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-08

7.  A qualitative exploration of early assessment of innovative medical technologies.

Authors:  Iben Fasterholdt; Anne Lee; Kristian Kidholm; Knud Bonnet Yderstræde; Kjeld Møller Pedersen
Journal:  BMC Health Serv Res       Date:  2018-11-06       Impact factor: 2.655

8.  Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.

Authors:  Anna Miquel-Cases; Valesca P Retèl; Bianca Lederer; Gunter von Minckwitz; Lotte M G Steuten; Wim H van Harten
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

Review 9.  Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.

Authors:  Maarten J IJzerman; Hendrik Koffijberg; Elisabeth Fenwick; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.